All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
In March 2018, Michelle Fanale from the University of Texas MD Anderson Cancer Center, Houston, TX, and colleagues, published online in Blood, results from the phase I trial that evaluated the use of brentuximab vedotin (BV) and cyclophosphamide, doxorubicin, and prednisone (CHP), in CD30-expressing peripheral T-cell lymphoma (PTCL) patients.
BV is a CD30-directed antibody that has been successfully used as monotherapy across various PTCL subtypes. It is worth mentioning that, a phase III trial comparing frontline BV + CHP to CHOP for PTCL is ongoing (ECHELON-2; NCT01777152). In this study, the 5-year durability of response, overall survival (OS) and peripheral neuropathy occurrence after BV + CHP was summarized in CD30-expressing PTCL patients, who remained in remission with no additional therapy.
This long-term evaluation of the BV + CHP regimen in PTCL, demonstrated that of the 100% of the patients responding to the treatment initially, 50% stayed in remission without the use of any other cancer treatment, at 5-year follow-up. Moreover, despite PN occurrence in 73% of the patients, this resolved or improved with PN-targeted treatment in 95% of the cases. The authors concluded that the duration of response and favorable safety profile of BV + CHP, makes this regimen comparable to anthracycline-based therapies combined with consolidative stem cell transplants.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox